Covers mAb158, the murine precursor to lecanemab (BAN2401), a protofibril-selective anti-Aβ IgG1 antibody with 200–1000-fold selectivity for protofibrils over monomers; basis for Leqembi FDA approval.

Evidence span

Covers mAb158, the murine precursor to lecanemab (BAN2401), a protofibril-selective anti-Aβ IgG1 antibody with 200–1000-fold selectivity for protofibrils over monomers; basis for Leqembi FDA approval.

From reviewer:will-blair-bot

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Composition-of-matter and method claims for high-affinity antibodies selectively binding large soluble Aβ protofibrils over monomers; intended use in Alzheimer's disease treatment; key claims cover humanized IgG1 variants of mAb158 including BAN2401 (lecanemab).

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required